Methods and compositions for cancer treatment
US-2024424094-A1 · Dec 26, 2024 · US
Therapeutic compositions comprising n-alkyl-hydroxy polymers
US10881682B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10881682-B2 |
| Application number | US-201514836614-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 26, 2015 |
| Priority date | Aug 26, 2015 |
| Publication date | Jan 5, 2021 |
| Grant date | Jan 5, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure describes methods and therapeutic compositions comprising polymers modified with N-alkyl-hydroxy groups comprising one or more carbon atoms. The compositions are useful for gene delivery, and exhibit broad-spectrum antiviral activity and low toxicity in vitro.
First claim
Opening claim text (preview).
What is claimed is: 1. A therapeutic composition, comprising: at least one polymer comprising: alkyl-hydroxy groups, amine groups located at the ends of the polymer chain, the polymer chain having a number average molecular weight of from about 5,000 Da to about 20,000 Da, secondary amine groups integrated into the polymer chain backbone, wherein: at least 5% of the amine groups located at the ends of the polymer chain comprise N-alkyl-hydroxy groups, at least a portion of the amine groups located at the ends of the polymer chain are saturated with N-alkyl-hydroxy groups, wherein each N-alkyl-hydroxy group comprises 1,2-diol, and the secondary amine groups integrated into the polymer chain backbone do not include N-alkyl-hydroxy groups. 2. The therapeutic composition of claim 1 , wherein the polymer chain is selected from the group consisting of: polyethylenimine, polyvinylamine, polyallylamine, polyamino acrylates, polyamino methacrylates, and copolymers and salts thereof. 3. The therapeutic composition of claim 1 , wherein at least a portion of the N-alkyl-hydroxy groups contain two or more carbon atoms. 4. The therapeutic composition of claim 3 , wherein at least a portion of the N-alkyl-hydroxy groups comprises an epoxide adduct. 5. The therapeutic composition of claim 3 , wherein at least a portion of the N-alkyl-hydroxy groups comprises a sugar adduct. 6. The therapeutic composition of claim 1 , wherein the polymer comprises N-alkyl-hydroxy groups that are virus binding groups. 7. The therapeutic composition of claim 1 , wherein the polymer comprises a linear chain. 8. The therapeutic composition of claim 1 , wherein the polymer chain is a copolymer. 9. A therapeutic composition, comprising: at least one polymer comprising: alkyl-hydroxy groups, amine groups located at the ends of the polymer chain, the polymer chain selected from the group consisting of polyethyleneimine, polyvinylamine, polyallylamine, polyamino acrylates, polyamino methacrylates, and copolymers and salts thereof, the polymer chain having a number average molecular weight of from 10,000 Da to about 20,000 Da, secondary amine groups integrated into the polymer chain backbone, wherein: at least 5% of the amine groups located at the ends of the polymer chain comprise N-alkyl-hydroxy groups, at least a portion of the amine groups located at the ends of the polymer chain are saturated with N-alkyl-hydroxy groups, at least a portion of the N-alkyl-hydroxy groups comprises a 1,2-diol, and the secondary amine groups integrated into the polymer chain backbone do not include N-alkyl-hydroxy groups. 10. The therapeutic composition of claim 9 , wherein the polymer chain is linear. 11. The therapeutic composition of claim 9 , wherein the polymer chain is a copolymer. 12. The therapeutic composition of claim 9 , wherein at least a portion of the N-alkyl-hydroxy groups contain two or more carbon atoms. 13. The therapeutic composition of claim 12 , wherein at least a portion of the N-alkyl-hydroxy groups comprises an epoxide adduct. 14. The therapeutic composition of claim 12 , wherein at least a portion of the N-alkyl-hydroxy groups comprises a sugar adduct.
Assignees
Inventors
Classifications
- A61K31/7088Primary
Compounds having three or more nucleosides or nucleotides · CPC title
obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes · CPC title
Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10881682B2 cover?
- The disclosure describes methods and therapeutic compositions comprising polymers modified with N-alkyl-hydroxy groups comprising one or more carbon atoms. The compositions are useful for gene delivery, and exhibit broad-spectrum antiviral activity and low toxicity in vitro.
- Who is the assignee on this patent?
- IBM
- What technology area does this patent fall under?
- Primary CPC classification A61K31/7088. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).